BeOne Medicines Ltd. (ONC) Form 10-Q — Aug 5, 2026

$ONCForm 10-QFiled Aug 5, 2026, 6:04 AM ET0001628280-26-052878Original filing

BeOne Medicines (formerly BeiGene) reported Q2 2026 total revenues of $1.71 billion, up 30% year over year, with net income of $237.0 million, up 151% from $94.3 million a year ago. GAAP diluted EPS was $0.16 per share ($2.05 per ADS), while non-GAAP diluted EPS per ADS came in at $3.84. Growth was driven by global BRUKINSA sales of $1.25 billion (+31.4%), TEVIMBRA sales of $228.5 million (+18.1%), and $157.3 million of Amgen product sales in China. Gross margin on product sales expanded to 89.6% from 87.4%, and cash and cash equivalents reached $5.10 billion against total debt of $1.07 billion.

Key figures

Eps: $0.16 basic / $0.16 diluted per share ($2.12 / $2.05 per ADS) for Q2 2026; non-GAAP diluted EPS per ADS $3.84
Revenue: $1,705.1 million (Q2 2026); $3,218.5 million (H1 2026)
Net Income: $237.0 million (Q2 2026), +151.3% YoY; $464.4 million (H1 2026), +385.8% YoY
Total Debt: $1,073.1 million (excluding $906.3 million royalty monetization liability)
Revenue Yoy: +29.6% (Q2 2026 YoY); +32.3% (H1 2026 YoY)
Total Assets: $9,175.6 million as of June 30, 2026
Cash Position: $5,098.0 million cash and cash equivalents as of June 30, 2026 ($5,280.7 million including restricted cash)
Shares Outstanding: 1478124405
Gross margin q2: 89.6% of product sales vs 87.4% prior year
Free cash flow h1: $595.9 million
Royalty liability: $906.3 million sale of future IMDELLTRA royalty liability at 11.0% effective imputed interest rate
Brukinsa q2 revenue: $1,247.6 million (+31.4% YoY)
Operating income q2: $325.0 million (+269.9% YoY)
Tevimbra q2 revenue: $228.5 million (+18.1% YoY)
Brukinsa q2 us revenue: $892.5 million (+30.5% YoY)
Operating cash flow h1: $664.2 million
Debt due next 12 months: $201.1 million
Dta valuation allowance: ~$3.6 billion, full allowance maintained; possible near-term release signaled
Q2 discrete tax expense: ~$49.3 million, primarily $59.0 million China subsidiary tax audit settlement
Amgen products china q2 revenue: $157.3 million (+24.5% YoY)

Price after filing

1 day: 0.0%7 days: +11.2%30 days: +12.3%

Close on the filing date to close N calendar days later (from $323.01). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.